
    
      As a single agent, alpelisib will be administered at a starting dose of 350 mg orally once
      daily on a continuous dosing schedule and can be adjusted for toxicity per the
      recommendations in this protocol. No pretreatment will be given prior to the medication.

      We plan on treating this individual patient for a tentative period of 12 weeks at which time
      treating physician will reevaluate the patient's clinical and radiological response and
      further duration of treatment will be contingent on that assessment.
    
  